308 related articles for article (PubMed ID: 25085902)
1. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
[TBL] [Abstract][Full Text] [Related]
5. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
6. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.
Schultz N; Lopez E; Saleh-Gohari N; Helleday T
Nucleic Acids Res; 2003 Sep; 31(17):4959-64. PubMed ID: 12930944
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
[TBL] [Abstract][Full Text] [Related]
8. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase (PARP-1) and p53 independently function in regulating double-strand break repair in primate cells.
Süsse S; Scholz CJ; Bürkle A; Wiesmüller L
Nucleic Acids Res; 2004; 32(2):669-80. PubMed ID: 14757832
[TBL] [Abstract][Full Text] [Related]
10. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
11. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Chao OS; Goodman OB
Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
[TBL] [Abstract][Full Text] [Related]
12. Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy.
Choi YE; Park E
Biochem Biophys Res Commun; 2015 Mar; 458(3):520-524. PubMed ID: 25677620
[TBL] [Abstract][Full Text] [Related]
13. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
14. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
[TBL] [Abstract][Full Text] [Related]
15. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53.
Baumann C; Boehden GS; Bürkle A; Wiesmüller L
Nucleic Acids Res; 2006; 34(3):1036-49. PubMed ID: 16473854
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
Muñoz-Gámez JA; Martín-Oliva D; Aguilar-Quesada R; Cañuelo A; Nuñez MI; Valenzuela MT; Ruiz de Almodóvar JM; De Murcia G; Oliver FJ
Biochem J; 2005 Feb; 386(Pt 1):119-25. PubMed ID: 15456408
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
Tentori L; Portarena I; Bonmassar E; Graziani G
Cell Death Differ; 2001 May; 8(5):457-69. PubMed ID: 11423906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]